Overview
Morgan Stanley downgraded Beiersdorf and Henkel to "underweight" and lowered both firms' 12-month price targets, pointing to earnings risk as the main rationale for the change. Beiersdorf's new target is €77, reduced 8% from €84. Henkel's target was trimmed 2% to €66.50 from €68. Both companies had previously been rated "equal-weight."
Share prices and broker commentary
At the March 13 market close, Beiersdorf shares were quoted at €78.44 and Henkel at €70.08. In its note, Morgan Stanley added that "the risk is still skewed to the downside relative to HPC peers," reflecting a lower conviction in the earnings trajectory versus comparable home and personal care companies.
Beiersdorf: market share pressure and revised earnings
The brokers' downgrade for Beiersdorf was accompanied by concerns tied to retail scanner data and a weaker margin outlook. NielsenIQ scanner figures cited in the research showed that Nivea lost market share in Western Europe in every month from February 2025 through January 2026, with declines ranging between 20 and 120 basis points. A product launch by Epicelline into the Nivea portfolio in September 2025 brought only temporary relief before share losses resumed.
On the profitability front, Morgan Stanley reduced its fiscal year 2026 adjusted EBIT margin estimate for Beiersdorf to 13.5% from 13.7%. The underlying EPS forecast was lowered to €4.33 from €4.42 - a 2.1% downward revision. The brokerage's EPS estimate sits 4.0% below the Visible Alpha consensus figure of €4.51. Morgan Stanley reports that the stock is trading at roughly 18x calendar-year 2026 price-to-earnings on an all-in basis, or about 14.5x excluding cash.
Capital return assumptions were also updated. The dividend was held flat year-on-year, while buybacks were scaled back to €750 million over two years from a previous program of €500 million per annum. The firm set its fiscal 2026 organic sales growth forecast at 1.1%, which it notes lies at the low end of management's 1% to 3% guidance. The broker also flagged geopolitical and demand risks - the Middle East represents roughly 5% of group revenue and faces disruption risk, and the adhesives business is exposed to softer industrial demand.
Henkel: margins, sales and relative valuation
Morgan Stanley's note highlights that Henkel posted a fiscal year 2025 gross margin of 50.8%, the weakest among the European home and personal care peers covered by the broker. For comparison, the research lists L'Oreal at 74.3%, Haleon at 64.2%, and Beiersdorf at 57.7%.
For Henkel, adjusted EBIT for fiscal 2026 was trimmed to €3.04 billion from €3.12 billion, with the margin reduced by 30 basis points to 15.0%. Preferred share EPS was revised to €5.42 from €5.54. Morgan Stanley's fiscal 2026 sales estimate for Henkel is €20.31 billion, around 2.7% below the Visible Alpha consensus of €20.87 billion.
Valuation sits at approximately 13x calendar-year 2026 P/E, below peer multiples, but Morgan Stanley warned that the lower multiple does not fully offset the downside earnings risk on a 12-month view. Within the broker's European home and personal care coverage, Haleon, Reckitt and Unilever carry "overweight" ratings, L'Oreal is "equal-weight," and Beiersdorf and Henkel are the only names assigned "underweight." As of March 13, Morgan Stanley calculated implied downside of about 3% for Beiersdorf and 6% for Henkel.
Implications
The brokerage's actions combine market-share tracking, margin revisions and a conservative sales outlook to justify the downgrade. The note ties ongoing brand share erosion and weaker industrial demand to near-term earnings risk, leaving both stocks on the cautious side of Morgan Stanley's European home and personal care coverage.